Review reveals cross-regulation between NF-kB and p53 pathways in malignant cells, highlighting dual-axis targeting as an actionable therapeutic strategy.
NF-kB–p53 axis antagonism: A therapeutic opportunity in cancer treatment - IJPO- Print ISSN No: - 2394-6784 Online ISSN No:- 2394-6792 Article DOI No:- 10.18231/j.ijpo.2025.024, Indian Journal of Pathology and Oncology-Indian J Pathol Oncol
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: